|
1
|
Epstein MA, Achong BG and Barr YM: Virus
particles in cultured lymphoblasts from burkitt's lymphoma. Lancet.
1:702–703. 1964. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Farrell PJ: Epstein-barr virus and cancer.
Annu Rev Pathol. 14:29–53. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Klein G: Tumor associations of
EBV-historical perspectives. Curr Top Microbiol Immunol. 390:17–22.
2015.PubMed/NCBI
|
|
4
|
Niller HH, Wolf H and Minarovits J:
Regulation and dysregulation of Epstein-Barr virus latency:
Implications for the development of autoimmune diseases.
Autoimmunity. 41:298–328. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cohen JI: Primary immunodeficiencies
associated with EBV disease. Curr Top Microbiol Immunol.
390:241–265. 2015.PubMed/NCBI
|
|
6
|
Blackburn EH: Switching and signaling at
the telomere. Cell. 106:661–673. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Campisi J, Kim SH, Lim CS and Rubio M:
Cellular senescence, cancer and aging: The telomere connection. Exp
Gerontol. 36:1619–1637. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zvereva MI, Shcherbakova DM and Dontsova
OA: Telomerase: Structure, functions, and activity regulation.
Biochemistry (Mosc). 75:1563–1583. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gladych M, Wojtyla A and Rubis B: Human
telomerase expression regulation. Biochem Cell Biol. 89:359–376.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wright WE, Piatyszek MA, Rainey WE, Byrd W
and Shay JW: Telomerase activity in human germline and embryonic
tissues and cells. Dev Genet. 18:173–179. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kyo S, Takakura M, Fujiwara T and Inoue M:
Understanding and exploiting hTERT promoter regulation for
diagnosis and treatment of human cancers. Cancer Sci. 99:1528–1538.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jafri MA, Ansari SA, Alqahtani MH and Shay
JW: Roles of telomeres and telomerase in cancer, and advances in
telomerase-targeted therapies. Genome Med. 8:692016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lü MH, Liao ZL, Zhao XY, Fan YH, Lin XL,
Fang DC, Guo H and Yang SM: hTERT-based therapy: A universal
anticancer approach (Review). Oncol Rep. 28:1945–1952. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mizukoshi E and Kaneko S:
Telomerase-targeted cancer immunotherapy. Int J Mol Sci.
20:18232019. View Article : Google Scholar
|
|
15
|
Kupchan SM, Court WA, Dailey RG Jr,
Gilmore CJ and Bryan RF: Triptolide and tripdiolide, novel
antileukemic diterpenoid triepoxides from Tripterygium
wilfordii. J Am Chem Soc. 94:7194–7195. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wong KF, Yuan Y and Luk JM:
Tripterygium wilfordii bioactive compounds as anticancer and
anti-inflammatory agents. Clin Exp Pharmacol Physiol. 39:311–320.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hou W, Liu B and Xu H: Triptolide:
Medicinal chemistry, chemical biology and clinical progress. Eur J
Med Chem. 176:378–392. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Noel P, Von Hoff DD, Saluja AK, Velagapudi
M, Borazanci E and Han H: Triptolide and its derivatives as cancer
therapies. Trends Pharmacol Sci. 40:327–341. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang W, Chen M, Xiao C, Yang W, Qin Q,
Tan Q, Liang Z, Liao X, Mao A and Wei C: Triptolide suppresses
growth of breast cancer by targeting HMGB1 in vitro and in vivo.
Biol Pharm Bull. 42:892–899. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liang X, Xie R, Su J, Ye B, Wei S, Liang
Z, Bai R, Chen Z, Li Z and Gao X: Inhibition of RNA polymerase III
transcription by Triptolide attenuates colorectal tumorigenesis. J
Exp Clin Cancer Res. 38:2172019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang W, He T, Chai C, Yang Y, Zheng Y,
Zhou P, Qiao X, Zhang B, Liu Z, Wang J, et al: Triptolide inhibits
the proliferation of prostate cancer cells and down-regulates
SUMO-specific protease 1 expression. PLoS One. 7:e376932012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou H, Guo W, Long C, Wang H, Wang J and
Sun X: Triptolide inhibits proliferation of Epstein-Barr
virus-positive B lymphocytes by down-regulating expression of a
viral protein LMP1. Biochem Biophys Res Commun. 456:815–820. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Long C, Wang J, Guo W, Wang H, Wang C, Liu
Y and Sun X: Triptolide inhibits transcription of hTERT through
down-regulation of transcription factor specificityprotein 1 in
primary effusion lymphoma cells. Biochem Biophys Res Commun.
469:87–93. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang J, Jiang J, Chen H, Wang L, Guo H,
Yang L, Xiao D, Qing G and Liu H: FDA-approved drug screen
identifies proteasome as a synthetic lethal target in MYC-driven
neuroblastoma. Oncogene. 38:6737–6751. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Long C, Guo W, Zhou H, Wang J, Wang H and
Sun X: Triptolide decreases expression of latency-associated
nuclear antigen 1 and reduces viral titers in Kaposi's
sarcoma-associated and herpesvirus-related primary effusion
lymphoma cells. Int J Oncol. 48:1519–1530. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Beishline K and Azizkhan-Clifford J: Sp1
and the ‘hallmarks of cancer’. FEBS J. 282:224–258. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Verma SC, Borah S and Robertson ES:
Latency-associated nuclear antigen of Kaposi's sarcoma-associated
herpesvirus up-regulates transcription of human telomerase reverse
transcriptase promoter through interaction with transcription
factor Sp1. J Virol. 78:10348–10359. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dang CV, O'Donnell KA, Zeller KI, Nguyen
T, Osthus RC and Li F: The c-Myc target gene network. Semin Cancer
Biol. 16:253–264. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pica F, Serafino A, Garaci E and Volpi A:
Cidofovir on HHV-8 in BCBL-1 cells. Antivir Ther. 9:823–825.
2004.PubMed/NCBI
|
|
31
|
Miller G, El-Guindy A, Countryman J, Ye J
and Gradoville L: Lytic cycle switches of oncogenic human
gammaherpesviruses. Adv Cancer Res. 97:81–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Y, Sun M, Shi W, Yang Q, Chen C,
Wang Z and Zhou X: Arsenic trioxide suppresses transcription of
hTERT through down-regulation of multiple transcription factors in
HL-60 leukemia cells. Toxicol Lett. 232:481–489. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Meyer N and Penn LZ: Reflecting on 25
years with MYC. Nat Rev Cancer. 8:976–990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cong YS, Wen J and Bacchetti S: The human
telomerase catalytic subunit hTERT: Organization of the gene and
characterization of the promoter. Hum Mol Genet. 8:137–142. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Toaldo C, Pizzimenti S, Cerbone A,
Pettazzoni P, Menegatti E, Daniela B, Minelli R, Giglioni B,
Dianzani MU, Ferretti C and Barrera G: PPARgamma ligands inhibit
telomerase activity and hTERT expression through modulation of the
Myc/Mad/Max network in colon cancer cells. J Cell Mol Med.
14:1347–1357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsurumi T, Fujita M and Kudoh A: Latent
and lytic Epstein-Barr virus replication strategies. Rev Med Virol.
15:3–15. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kerr JR: Epstein-Barr virus (EBV)
reactivation and therapeutic inhibitors. J Clin Pathol. 72:651–658.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kanda T: EBV-encoded latent genes. Adv Exp
Med Biol. 1045:377–394. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
McKenzie J and El-Guindy A: Epstein-barr
virus lytic cycle reactivation. Curr Top Microbiol Immunol.
391:237–261. 2015.PubMed/NCBI
|
|
40
|
Bhende PM, Seaman WT, Delecluse HJ and
Kenney SC: BZLF1 activation of the methylated form of the BRLF1
immediate-early promoter is regulated by BZLF1 residue 186. J
Virol. 79:7338–7348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tikhmyanova N, Paparoidamis N,
Romero-Masters J, Feng X, Mohammed FS, Reddy PAN, Kenney SC,
Lieberman PM and Salvino JM: Development of a novel inducer for EBV
lytic therapy. Bioorg Med Chem Lett. 29:2259–2264. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Murata T and Tsurumi T: Switching of EBV
cycles between latent and lytic states. Rev Med Virol. 24:142–153.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ben Yebdri F, Van Grevenynghe J, Tang VA,
Goulet ML, Wu JH, Stojdl DF, Hiscott J and Lin R:
Triptolide-mediated inhibition of interferon signaling enhances
vesicular stomatitis virus-based oncolysis. Mol Ther. 21:2043–2053.
2013. View Article : Google Scholar : PubMed/NCBI
|
